Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT
- Cardiac Electrophysiology Key Opinion Leaders to include
Bruce Stambler, MD and Sean Pokorney, MD
- Conference call and webcast on
Thursday, April 21, 2022at 1:00 p.m. ET
MONTREAL and CHARLOTTE, N.C.,
The agenda for the event will include an overview of PSVT, including the current treatment landscape and patient and healthcare system burdens, a review of the existing etripamil dataset in patients with PSVT, and a discussion of the potential commercial opportunity.
Bruce Stambler, MD, FHRS, Director of Cardiac Arrhythmia Researchand Education, Piedmont Heart Institute, Atlanta, GA Sean Pokorney, MD, MBA, Director of the Arrhythmia Core Laboratory, Duke Clinical Research Institute, Assistant Professor of Medicine, Duke University School of Medicine, Durham, NC
Conference Call and Webcast
To access a live or recorded webcast of the event and accompanying slides, please visit the News & Events section of Milestone's website at www.milestonepharma.com. To access the live call by phone, dial (203) 518-9713 (domestic) or (866) 518-6930 (international) and enter the passcode 2230168. The recorded webcast and slides will be available on the Company's website following the call.
About Paroxysmal Supraventricular Tachycardia
Paroxysmal supraventricular tachycardia (PSVT) is a condition characterized by intermittent episodes of rapid heartbeat that starts and stops suddenly and without warning that
Etripamil, Milestone's lead investigational product, is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions. As a nasal spray that is self-administered by the patient, etripamil has the potential to shift the current treatment experience for many patients from the emergency department to a medically-unsupervised setting. Milestone is conducting a comprehensive development program for etripamil, with Phase 3 trials ongoing in paroxysmal supraventricular tachycardia (PSVT) and a Phase 2 proof-of-concept trial underway in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR).
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "will," "expect," "continue," "estimate," "potential," "progress" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential of etripamil to serve as a promising therapy for PSVT patients, the design, progress, timing, scope and results of the RAPID and ReVeRA trials; Milestone's ability to execute on the remainder of the PSVT program, Milestone's ongoing plans to study etripamil in atrial fibrillation patients, the sufficiency of Milestone's current cash resources to support its operations, and estimates about the addressable market and commercial potential for treatments of atrial fibrillation with rapid ventricular rate. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation, enrollment, completion and evaluation of clinical trials, and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, as well as risks related to pandemics and public health emergencies, including those related to the ongoing COVID-19 pandemic, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital. These and other risks are set forth in Milestone's filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-host-virtual-key-opinion-leader-event-on-etripamil-for-the-treatment-of-psvt-301525400.html